snx-5422
Small moleculeexperimental
Clinical trial activity
13 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00506805)
Timeline
Indications
Mechanism of action
- HSP90INHIBITOR
HSP90 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pf04929113
- pf 04929113
- pf-04929113
- snx-5422
- snx-5422
- snx-5422
- snx-5422
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02973399 | Phase 1 | Feb 7, 2017 | Esanex Inc. |
| NCT02914327 | Phase 1 | Feb 2, 2017 | Esanex Inc. |
| NCT02612285 | Phase 2 | Mar 1, 2016 | Esanex Inc. |
| NCT02063958 | Phase 1 | Feb 1, 2014 | Esanex Inc. |
| NCT01635712 | Phase 1 | Feb 1, 2014 | Esanex Inc. |
| NCT01892046 | Phase 1 | Nov 1, 2013 | Esanex Inc. |
| NCT01848756 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2013 | Esanex Inc. |
| NCT01851096 | Phase 1 | Mar 1, 2013 | Esanex Inc. |
| NCT01611623 | Phase 1 | May 1, 2012 | Esanex Inc. |
| NCT00644072 | Phase 1 | Mar 7, 2008 | National Cancer Institute (NCI) |
| NCT00647764 | Phase 1 | Mar 1, 2008 | Esanex Inc., National Cancer Institute (NCI), Pfizer |
| NCT00595686 | Phase 1 | Jan 1, 2008 | Esanex Inc., Pfizer, Serenex |
| NCT00506805 | Phase 1 | Jun 1, 2007 | Esanex Inc., Pfizer, Serenex |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Esanex Inc. | For profit | 12 | 12 | 2 | 2007 |
| Pfizer | For profit | 3 | 0 | 1 | 2007 |
| National Cancer Institute (NCI) | Government | 2 | 1 | 1 | 2008 |
| Serenex | For profit | 2 | 0 | 1 | 2007 |
4 organizations
Page 1 / 1